1 / 31

Basic Clinician Training Module 5

Basic Clinician Training Module 5. Hypercoagulable states. Introduction. A prothrombotic or hypercoagulable state can be the result of: Hyperactive platelet function and/or Hyperactive coagulation cascade function

sharon-carney
Download Presentation

Basic Clinician Training Module 5

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Basic Clinician TrainingModule 5 Hypercoagulable states

  2. Introduction • A prothrombotic or hypercoagulable state can be the result of: • Hyperactive platelet function and/or • Hyperactive coagulation cascade function • Proper assessment of the factor(s) contributing to a hypercoagulable state is necessary to determine proper pharmacological intervention to prevent the development of a thrombotic event.

  3. Importance of assessing the hypercoagulable state % with Thrombotic complication MA range Percentage of Patients with a Thrombotic Complication By Quartiles of MA Value McGrath DJ et al. Anesth Analg 96: SCA1-141, 2003

  4. Insert graph from Sinai study

  5. Assessing hypercoagulability with the TEG • TEG analysis can demonstrate hypercoagulable as well as hypocoagulable states • TEG analysis can differentiate between platelet hypercoagulability and enzymatic hypercoagulability.

  6. Hypercoagulable statesPlatelet vs. enzymatic • Hyperactive platelet function is characterized by rapid clot development and abnormally high clot strength. • Hyper enzymatic pathway activity is characterized by rapid fibrin formation with subsequent clot formation.

  7. Platelet hypercoagulability • Characterized by rapid clot development with higher than normal clot strength due to hyperactive platelet function. • Probable causes: • Diminished endogenous platelet inhibitory mechanisms • High platelet numbers • Abnormal generation of platelet activators • Inflammatory mediators

  8. Platelet hypercoagulabilityCommon conditions • Antithrombin III deficiency • Thrombomodulin-Protein C dysfunction or APC resistance • Diminished nitric oxide synthesis/release • Dysplasminogenemia • High plasminogen activator inhibitor • Hyperhomocysteinemia • Malignancy • DIC

  9. Platelet hypercoagulabilityAs shown by TEG Patient status: high risk for thrombotic event Probable cause: Rapid clot formation and strong clot development Common treatment: Platelet inhibitor

  10. Platelet hypercoagulabilityTreatment considerations • Step 1: Identify and quantify prothrombotic state • Step 2: Determine therapeutic response of anti-platelet therapies • WHY?: Patient resistance to aspirin and clopidogrel has been documented in the literature • HOW?: TEG analysis combined with PlateletMapping assay (Module 6). • Assesses platelet inhibition against total platelet function • Provides personalized treatment regimen

  11. Platelet hypercoagulabilityCommon therapy algorithm

  12. Enzymatic hypercoagulability • Characterized by rapid fibrin generation with subsequent clot formation • Probable cause(s): • Loss of antithrombotic protective mechanisms • APC resistance (Factor V Leiden) • ATIII deficiency • Dysfibrinogenemia

  13. Enzymatic hypercoagulabilityAs shown by TEG analysis Patient status: high risk for thrombotic event Probable cause: Rapid thrombin generation and subsequent clot formation Common treatment: Anticoagulation

  14. Enzymatic hypercoagulabilitySpecial considerations • Treatment ultimately depends on clinical situation • Goal is to prevent clot formation • Common inpatient treatment: heparin, LMWH, APC (activate protein C) • Common outpatient treatment: LMWH or Coumadin to maintain INR > 2.0 • If clots have already formed - may require fibrinolytic agent before anticoagulation

  15. Platelet & enzymatic hypercoagulabilityCommon conditions • Heart assist device • Lupus anticoagulant • Cancer • Orthopedic surgery • Pregnancy • Trauma • Burns • Sepsis

  16. Platelet & enzymatic hypercoagulabilityAs shown by TEG analysis Patient status: high risk for thrombotic event • Probable cause(s): • Rapid thrombin generation • Excessive platelet function • Common treatment(s): • Anticoagulation and/or • Platelet inhibitor

  17. Interpretation Exercises Prothrombotic states

  18. Exercise 1 • Using the TEG Decision Tree, what is your interpretation of this tracing? • (select all that apply) • Platelet hypercoagulability • Enzymatic hypercoagulability • Platelet and enzymatic hypercoagulability • Secondary fibrinolysis • What would be an appropriate treatment, if any for this patient? Answer Next

  19. Exercise 2 • Using the TEG Decision Tree, what is your interpretation of this tracing? • (select all that apply) • Platelet hypercoagulability • Enzymatic hypercoagulability • Platelet and enzymatic hypercoagulability • Secondary fibrinolysis • What would be an appropriate treatment, if any for this patient? Answer Next

  20. Exercise 3: Off-pump CABG patient Kaolin with heparinase Green: Pre-op Black: Before protamine • The above are tracings from a patient who has undergone an off-pump • CABG. What is this patient’s current hemostatic state (black tracing)? • Platelet hypercoagulability • Enzymatic hypercoagulability • Platelet and enzymatic hypercoagulability • Secondary fibrinolysis • What would be an appropriate treatment, if any for this patient? Answer Next

  21. Exercise 4 • Using the TEG Decision Tree, what is your interpretation of this tracing? • (select all that apply) • Platelet hypercoagulability • Enzymatic hypercoagulability • Platelet and enzymatic hypercoagulability • Secondary fibrinolysis • What would be an appropriate treatment, if any for this patient? Answer Next

  22. Exercise 5 • Using the TEG Decision Tree, what is your interpretation of this tracing? • (select all that apply) • Platelet hypercoagulability • Enzymatic hypercoagulability • Platelet and enzymatic hypercoagulability • Secondary fibrinolysis • What would be an appropriate treatment, if any, for this patient? Answer Next

  23. Exercise 6 • Using the TEG Decision Tree, what is your interpretation of this tracing? • (select all that apply) • Platelet hypercoagulability • Enzymatic hypercoagulability • Platelet and enzymatic hypercoagulability • Secondary fibrinolysis • If this was a tracing from a pre-bypass cardiac surgical patient, • what type of antifibrinolytic treatment would you consider? Answer Next

  24. Exercise 1 • Using the TEG Decision Tree, what is your interpretation of this tracing? • (select all that apply) • Platelet hypercoagulability • Enzymatic hypercoagulability • Platelet and enzymatic hypercoagulability • Secondary fibrinolysis • What would be an appropriate treatment, if any for this patient? • Consider an anti-platelet agent. Back Next

  25. Exercise 2 • Using the TEG Decision Tree, what is your interpretation of this tracing? • (select all that apply) • Platelet hypercoagulability • Enzymatic hypercoagulability • Platelet and enzymatic hypercoagulability • Secondary fibrinolysis • What would be an appropriate treatment, if any for this patient? • Consider treatment with both an anticoagulant and anti-platelet • agent. Back Next

  26. Exercise 3: Off-pump CABG patient Kaolin with heparinase Green: Pre-op Black: Before protamine • The above are tracings from a patient who has undergone an off-pump • CABG. What is this patient’s current hemostatic state (black tracing)? • Platelet hypercoagulability • Enzymatic hypercoagulability • Platelet and enzymatic hypercoagulability • Secondary fibrinolysis • What would be an appropriate treatment, if any for this patient? • Although the R value is within normal range, the pre-op value was • lower than normal. Consider half the normal protamine dose plus • an anti-platelet agent. Back Next

  27. Exercise 4 • Using the TEG Decision Tree, what is your interpretation of this tracing? • (select all that apply) • Platelet hypercoagulability • Enzymatic hypercoagulability • Platelet and enzymatic hypercoagulability • Secondary fibrinolysis • What would be an appropriate treatment, if any for this patient? • Consider treatment with an anticoagulant. Back Next

  28. Exercise 5 • Using the TEG Decision Tree, what is your interpretation of this tracing? • (select all that apply) • Platelet hypercoagulability • Enzymatic hypercoagulability • Platelet and enzymatic hypercoagulability • Secondary fibrinolysis • What would be an appropriate treatment, if any, for this patient? • Consider an anticoagulant plus an anti-platelet agent. Back Next

  29. Exercise 6 • Using the TEG Decision Tree, what is your interpretation of this tracing? • (select all that apply) • Platelet hypercoagulability • Enzymatic hypercoagulability • Platelet and enzymatic hypercoagulability • Secondary fibrinolysis • If this was a tracing from a pre-bypass cardiac surgical patient, • what type of antifibrinolytic treatment would you consider? Since the patient • is hypercoagulable, treatment with an antifibrinolytic agent may be contra- • indicated at this phase in the surgery. Repeat a TEG during CPB to determine • if fibrinolysis has developed and treat accordingly. Back Next

  30. End of Module 5

More Related